Anti-IgLON5 disease

Anti-IgLON5 disease
Synonyms
Pronounce	N/A
Specialty	Neurology
Symptoms	Sleep disorder, movement disorder, cognitive dysfunction, bulbar dysfunction
Complications	N/A
Onset	Typically in adulthood
Duration	Chronic
Types	N/A
Causes	Autoimmune disease
Risks
Diagnosis	Clinical diagnosis, antibody testing
Differential diagnosis	Neurodegenerative disease, other autoimmune encephalitis
Prevention	N/A
Treatment	Immunotherapy, symptomatic treatment
Medication	N/A
Prognosis	Variable, often progressive
Frequency	Rare
Deaths	N/A

A rare neurological disorder associated with sleep disturbances and neurodegeneration

Anti-IgLON5 disease is a rare neurological disorder characterized by a combination of sleep disturbances, movement disorders, and neurodegeneration. It is associated with the presence of antibodies against the IgLON5 protein, which is involved in cell adhesion in the nervous system.

Pathophysiology

Anti-IgLON5 disease is an autoimmune disorder where the body's immune system mistakenly attacks the IgLON5 protein. This protein is part of the IgLON family of cell adhesion molecules, which play a crucial role in the development and maintenance of the central nervous system. The presence of anti-IgLON5 antibodies leads to neuroinflammation and neurodegeneration, particularly affecting the brainstem and hypothalamus.

Clinical Features

The clinical presentation of anti-IgLON5 disease is diverse, but it primarily affects sleep and movement. Common symptoms include:

• Sleep disorders: Patients often experience REM sleep behavior disorder, sleep apnea, and insomnia.
• Movement disorders: These can include ataxia, dystonia, and chorea.
• Cognitive impairment: Some patients may develop dementia or other cognitive deficits.
• Bulbar symptoms: Such as dysphagia and dysarthria.

Diagnosis

Diagnosis of anti-IgLON5 disease involves a combination of clinical evaluation, neuroimaging, and laboratory tests. The presence of anti-IgLON5 antibodies in the cerebrospinal fluid or serum is a key diagnostic marker. MRI scans may show atrophy in specific brain regions, and polysomnography can be used to assess sleep disturbances.

Treatment

There is currently no cure for anti-IgLON5 disease, and treatment focuses on managing symptoms. Options may include:

• Immunotherapy: Such as corticosteroids, intravenous immunoglobulin, or plasmapheresis.
• Symptomatic treatment: For sleep disorders, CPAP therapy may be used for sleep apnea, and medications like clonazepam can help with REM sleep behavior disorder.
• Physical therapy: To manage movement disorders and maintain mobility.

Prognosis

The prognosis of anti-IgLON5 disease varies. Some patients experience a slow progression of symptoms, while others may have a more rapid decline. The disease can lead to significant disability and may be life-threatening due to complications such as severe sleep apnea.

Related pages

• Autoimmune encephalitis
• Sleep disorder
• Neurodegenerative disease